Comparative Pharmacology
Head-to-head clinical analysis: ACETOHEXAMIDE versus CHLORPROPAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETOHEXAMIDE versus CHLORPROPAMIDE.
ACETOHEXAMIDE vs CHLORPROPAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels (K_ATP), causing membrane depolarization, calcium influx, and exocytosis of insulin-containing granules. Also may increase peripheral insulin sensitivity.
Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, increasing intracellular calcium, and enhancing peripheral insulin sensitivity. Also reduces hepatic glucose production.
Initial: 250 mg orally once daily; maintenance: 250-1500 mg orally once daily or in divided doses twice daily.
Initial: 250 mg orally once daily. Maintenance: 100-500 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateChlorpropamide + Gatifloxacin
"Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateChlorpropamide + Rosoxacin
"Chlorpropamide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateChlorpropamide + Levofloxacin
"Chlorpropamide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateChlorpropamide + Trovafloxacin
Terminal elimination half-life: 6-12 hours (parent drug); ~5-6 hours (active metabolite hydroxyhexamide); clinical context: prolonged in renal impairment due to accumulation of active metabolite
36 hours (range 25-60 hours). Prolonged in renal impairment due to cumulative effects and hypoglycemia risk.
Renal: 85-90% (60-70% as unchanged drug, remainder as hydroxylated metabolite); biliary/fecal: <10%
Renal excretion of unchanged drug (80-90%) and hepatic metabolites (10-20%). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic
"Chlorpropamide may increase the hypoglycemic activities of Trovafloxacin."